Skip to main content
SpringerLink
Log in

Hepatocellular Carcinoma: Western Experience

  • Chapter
  • First Online:
Image-Guided Interventions in Oncology

  • 377 Accesses

Abstract

The etiology and management of hepatocellular carcinoma varies greatly across the United States and the world at large. Guidelines are continuously evolving, and there is currently no single standard of care for American patients with advanced hepatocellular carcinoma. Technical advances have made even complex minimally invasive therapies more feasible and widely available, while a variety of novel systemic therapies continue to be developed. Interventional Oncologists are increasing able to provide curative-intent treatments for early-stage hepatocellular carcinoma patients. These developments have also contributed to improved outcomes and innovative, personalized treatment paradigms for patients with later stage disease.

The following is a condensed review of the contemporary diagnosis and clinical management of hepatocellular carcinoma, with an emphasis on the current standards of care in the United States. Integrative, multidisciplinary care plays a large role in the continued effort to reduce the morbidity and mortality associated with this debilitating malignancy. For further reference, the current treatment guidelines from the American Association for the Study of Liver Diseases (AASLD) are cited with other Key Readings at the conclusion of the chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–14.

    Article  PubMed  Google Scholar 

  2. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, Schirmacher P, Vilgrain V. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.

    Article  Google Scholar 

  3. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma: Heimbach et al. Hepatology. 2018;67:358–80.

    Article  PubMed  Google Scholar 

  4. Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol. 2018;43:13–25.

    Article  Google Scholar 

  5. Jindal A, Thadi A, Shailubhai K. Hepatocellular carcinoma: etiology and current and future drugs. J Clin Exp Hepatol. 2019;9:221–32.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723–50.

    Article  PubMed  Google Scholar 

  7. Welzel TM, Graubard BI, Quraishi S, Zeuzem S, Davila JA, El-Serag HB, McGlynn KA. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol. 2013;108:1314–21.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases: Hepatology, Vol. XX, No. X, 2017. Hepatology. 2018;67:328–57.

    Article  PubMed  Google Scholar 

  9. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57:1357–65.

    Article  CAS  PubMed  Google Scholar 

  10. Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23:8263–76.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Dolganiuc A. Alcohol and viral hepatitis: role of lipid rafts. Alcohol Res Curr Rev. 2015;37:299–309.

    Google Scholar 

  12. Alferink L, Kiefte-de Jong J, Darwish Murad S. Potential mechanisms underlying the role of coffee in liver health. Semin Liver Dis. 2018;38:193–214.

    Article  CAS  PubMed  Google Scholar 

  13. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002;31:339–46.

    Article  CAS  PubMed  Google Scholar 

  14. Pinyol R, Montal R, Bassaganyas L, et al. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut. 2019;68:1065–75.

    Article  PubMed  CAS  Google Scholar 

  15. Ren A-H, Zhao P-F, Yang D-W, Du J-B, Wang Z-C, Yang Z-H. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017: LI-RADS v2018 of MRI for diagnosing HCC. J Magn Reson Imaging. 2019;50:746–55.

    Article  PubMed  Google Scholar 

  16. Llovet J, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–42.

    Article  CAS  PubMed  Google Scholar 

  17. Zipprich A, Garcia-Tsao G, Rogowski S, Fleig WE, Seufferlein T, Dollinger MM. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int. 2012;32:1407–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Khalaf N, Ying J, Mittal S, Temple S, Kanwal F, Davila J, El-Serag HB. Natural history of untreated hepatocellular carcinoma in a US cohort and the role of cancer surveillance. Clin Gastroenterol Hepatol. 2017;15:273–281.e1.

    Article  PubMed  Google Scholar 

  19. Lewandowski RJ, Gabr A, Abouchaleh N, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018;287:1050–8.

    Article  PubMed  Google Scholar 

  20. Fayek SA, Quintini C, Chavin KD, Marsh CL. The current state of liver transplantation in the United States: perspective from American Society of Transplant Surgeons (ASTS) Scientific Studies Committee and Endorsed by ASTS Council. Am J Transplant. 2016;16:3093–104.

    Article  CAS  PubMed  Google Scholar 

  21. Berzigotti A, Reig M, Abraldes JG, Bosch J, Bruix J. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology. 2015;61:526–36.

    Article  PubMed  Google Scholar 

  22. May B, Madoff D. Portal vein embolization: rationale, technique, and current application. Semin Interv Radiol. 2012;29:081–9.

    Article  Google Scholar 

  23. Xu X-L, Liu X-D, Liang M, Luo B-M. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: systematic review of randomized controlled trials with meta-analysis and trial sequential analysis. Radiology. 2018;287:461–72.

    Article  PubMed  Google Scholar 

  24. Huang Y, Shen Q, Bai HX, Wu J, Ma C, Shang Q, Hunt SJ, Karakousis G, Zhang PJ, Zhang Z. Comparison of radiofrequency ablation and hepatic resection for the treatment of hepatocellular carcinoma 2 cm or less. J Vasc Interv Radiol. 2018;29:1218–1225.e2.

    Article  PubMed  Google Scholar 

  25. Mironov O, Jaberi A, Kachura JR. Thermal ablation versus surgical resection for the treatment of stage T1 hepatocellular carcinoma in the surveillance, epidemiology, and end results database population. J Vasc Interv Radiol. 2017;28:325–33.

    Article  PubMed  Google Scholar 

  26. Lee HW, Lee JM, Yoon J-H, Kim YJ, Park J-W, Park S-J, Kim SH, Yi N-J, Suh K-S. A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma. Ann Surg Treat Res. 2018;94:74.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Ng KKC, Chok KSH, Chan ACY, Cheung TT, Wong TCL, Fung JYY, Yuen J, Poon RTP, Fan ST, Lo CM. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma: resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg. 2017;104:1775–84.

    Article  CAS  PubMed  Google Scholar 

  28. Thamtorawat S, Hicks RM, Yu J, Siripongsakun S, Lin W-C, Raman SS, McWilliams JP, Douek M, Bahrami S, Lu DSK. Preliminary outcome of microwave ablation of hepatocellular carcinoma: breaking the 3-cm barrier? J Vasc Interv Radiol. 2016;27:623–30.

    Article  PubMed  Google Scholar 

  29. Song KD. Percutaneous cryoablation for hepatocellular carcinoma. Clin Mol Hepatol. 2016;22:509–15.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Xu J, Noda C, Erickson A, Mokkarala M, Charalel R, Ramaswamy R, Tao Y, Akinwande O. Radiofrequency ablation vs. cryoablation for localized hepatocellular carcinoma: a propensity-matched population study. Anticancer Res. 2018;38:6381–6.

    Article  PubMed  Google Scholar 

  31. Chen R, Gan Y, Ge N, Chen Y, Wang Y, Zhang B, Wang Y, Ye S, Ren Z. Transarterial chemoembolization versus radiofrequency ablation for recurrent hepatocellular carcinoma after resection within Barcelona clinic liver Cancer stage 0/a: a retrospective comparative study. J Vasc Interv Radiol. 2016;27:1829–36.

    Article  PubMed  Google Scholar 

  32. Koh PS, Chan ACY, Cheung TT, Chok KSH, Dai WC, Poon RTP, Lo CM. Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis. HPB. 2015;1:72–8.

    Google Scholar 

  33. Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind J-FH. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data: Lencioni et al. Hepatology. 2016;64:106–16.

    Article  CAS  PubMed  Google Scholar 

  34. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.

    Article  PubMed  Google Scholar 

  35. Lo C. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–71.

    Article  CAS  PubMed  Google Scholar 

  36. Horikawa M, Miyayama S, Irie T, Kaji T, Arai Y. Development of conventional transarterial chemoembolization for hepatocellular carcinomas in Japan: historical, strategic, and technical review. Am J Roentgenol. 2015;205:764–73.

    Article  Google Scholar 

  37. Golfieri R, Cappelli A, Cucchetti A, Piscaglia F, Carpenzano M, Peri E, Ravaioli M, D’Errico-Grigioni A, Pinna AD, Bolondi L. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology. 2011;53:1580–9.

    Article  PubMed  Google Scholar 

  38. Kwan SW, Fidelman N, Ma E, Kerlan RK, Yao FY. Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver Transpl. 2012;18:727–36.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Kawaguchi T, Ohkawa K, Imanaka K, Tamai C, Kawada N, Ikezawa K, Uehara H, Itou Y, Nakanishi K, Katayama K. Lipiodol accumulation and Transarterial chemoembolization efficacy for HCC patients. Hepato-Gastroenterology. 2011; https://doi.org/10.5754/hge11258.

  40. Kim BK, Kim SU, Kim KA, et al. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. J Hepatol. 2015;62:1304–10.

    Article  PubMed  Google Scholar 

  41. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41–52.

    Article  PubMed  Google Scholar 

  42. Gao S, Yang Z, Zheng Z, Yao J, Deng M, Xie H, Zheng S, Zhou L. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepato-Gastroenterology. 2013;60:813–20.

    CAS  PubMed  Google Scholar 

  43. Golfieri R, Renzulli M, Cioni R, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111:255–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxì A, Cottone M. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224:47–54.

    Article  PubMed  Google Scholar 

  45. Brown KT, Do RK, Gonen M, et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol. 2016;34:2046–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Tong AKT, Kao YH, Too CW, Chin KFW, Ng DCE, Chow PKH. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol. 2016;89:20150943.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Padia SA, Johnson GE, Horton KJ, et al. Segmental Yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective, propensity score–matched study. J Vasc Interv Radiol. 2017;28:777–785.e1.

    Article  PubMed  Google Scholar 

  48. Iñarrairaegui M, Thurston KG, Bilbao JI, D’Avola D, Rodriguez M, Arbizu J, Martinez-Cuesta A, Sangro B. Radioembolization with use of Yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2010;21:1205–12.

    Article  PubMed  Google Scholar 

  49. Silva JP, Berger NG, Tsai S, Christians KK, Clarke CN, Mogal H, White S, Rilling W, Gamblin TC. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. HPB. 2017;19:659–66.

    Article  PubMed  Google Scholar 

  50. Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013;57:1826–37.

    Article  CAS  PubMed  Google Scholar 

  51. Garin E, Lenoir L, Edeline J, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40:1057–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Biederman DM, Titano JJ, Korff RA, Fischman AM, Patel RS, Nowakowski FS, Lookstein RA, Kim E. Radiation Segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma. J Vasc Interv Radiol. 2018;29:30–37.e2.

    Article  PubMed  Google Scholar 

  53. Lewandowski RJ, Donahue L, Chokechanachaisakul A, Kulik L, Mouli S, Caicedo J, Abecassis M, Fryer J, Salem R, Baker T. 90 Y radiation lobectomy: outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes: liver resection after 90 Y radiation lobectomy. J Surg Oncol. 2016;114:99–105.

    Article  PubMed  Google Scholar 

  54. Vouche M, Lewandowski RJ, Atassi R, et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol. 2013;59:1029–36.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Theysohn JM, Ertle J, Müller S, Schlaak JF, Nensa F, Sipilae S, Bockisch A, Lauenstein TC. Hepatic volume changes after lobar selective internal radiation therapy (SIRT) of hepatocellular carcinoma. Clin Radiol. 2014;69:172–8.

    Article  CAS  PubMed  Google Scholar 

  56. Facciorusso A, Serviddio G, Muscatiello N. Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: a systematic review and meta-analysis. World J Hepatol. 2016;8:770.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Mohamed M, Katz AW, Tejani MA, et al. Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma. Adv Radiat Oncol. 2016;1:35–42.

    Article  PubMed  Google Scholar 

  58. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

    Article  CAS  PubMed  Google Scholar 

  59. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.

    Article  CAS  PubMed  Google Scholar 

  60. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66.

    Article  CAS  PubMed  Google Scholar 

  61. Zhu AX, Park JO, Ryoo B-Y, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16:859–70.

    Article  CAS  PubMed  Google Scholar 

  62. Zhu AX, Kang Y-K, Yen C-J, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282–96.

    Article  CAS  PubMed  Google Scholar 

  63. Abou-Alfa GK, Meyer T, Cheng A-L, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Yau T, Park JW, Finn RS, et al. CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30:mdz394.029.

    Google Scholar 

  66. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940–52.

    Article  PubMed  Google Scholar 

  67. Finn RS, Ryoo B-Y, Merle P, et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2019;37:4004.

    Article  Google Scholar 

  68. Sheta E, El-Kalla F, El-Gharib M, Kobtan A, Elhendawy M, Abd-Elsalam S, Mansour L, Amer I. Comparison of single-session transarterial chemoembolization combined with microwave ablation or radiofrequency ablation in the treatment of hepatocellular carcinoma: a randomized-controlled study. Eur J Gastroenterol Hepatol. 2016;28:1198–203.

    Article  CAS  PubMed  Google Scholar 

  69. Ni J-Y. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol. 2013;19:3872.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Cao J, Zhou J, Zhang X, Ding X, Long Q. Meta-analysis on radiofrequency ablation in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Huazhong Univ Sci Technolog Med Sci. 2014;34:692–700.

    Article  CAS  PubMed  Google Scholar 

  71. Peng Z-W, Zhang Y-J, Chen M-S, Xu L, Liang H-H, Lin X-J, Guo R-P, Zhang Y-Q, Lau WY. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31:426–32.

    Article  PubMed  Google Scholar 

  72. Wang W, Zhang L, Ni J-Y, Jiang X, Chen D, Chen Y, Sun H, Luo J, Xu L. Radiofrequency ablation combined with transcatheter arterial chemoembolization therapy versus surgical resection for hepatocellular carcinoma within the Milan criteria: a meta-analysis. Korean J Radiol. 2018;19:613.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Takuma Y, Takabatake H, Morimoto Y, Toshikuni N, Kayahara T, Makino Y, Yamamoto H. Comparison of combined transcatheter arterial chemoembolization and radiofrequency ablation with surgical resection by using propensity score matching in patients with hepatocellular carcinoma within Milan criteria. Radiology. 2013;269:927–37.

    Article  PubMed  Google Scholar 

  74. Zhang R, Shen L, Zhao L, Guan Z, Chen Q, Wang L. Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma. Diagn Interv Radiol. 2018;24:219–24.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Fang A, Morel-Ovalle L, Kao J, Pereira K, Gadani S, Sherwani A, Vaheesan K. 04:21 PM abstract no. 217 retrospective comparison of conventional versus drug-eluting beads transarterial chemoembolization prior to microwave ablation (MWA) in patients with hepatocellular carcinoma (HCC). J Vasc Interv Radiol. 2019;30:S97–8.

    Article  Google Scholar 

  76. Rajyaguru DJ, Borgert AJ, Smith AL, Thomes RM, Conway PD, Halfdanarson TR, Truty MJ, Kurup AN, Go RS. Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: analysis of the National Cancer Database. J Clin Oncol. 2018;36:600–8.

    Article  CAS  PubMed  Google Scholar 

  77. Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS, Jang JW, Choi JY, Yoon SK, Chung KW. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer. 2010;10:475.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, Johnstone PAS, Cardenes HR. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol. 2011;81:e447–53.

    Article  Google Scholar 

  79. Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31:1631–9.

    Article  PubMed  Google Scholar 

  80. Jun BG, Kim YD, Cheon GJ, et al. Clinical significance of radiation-induced liver disease after stereotactic body radiation therapy for hepatocellular carcinoma. Korean J Intern Med. 2018;33:1093–102.

    Article  CAS  PubMed  Google Scholar 

  81. Gabr A, Ali R, Mora R, Sato K, Desai K, Mouli S, Riaz A, Salem R, Lewandowski R. 3:18 PM abstract no. 83 radiation segmentectomy vs. radiofrequency ablation in early stage hepatocellular carcinoma. J Vasc Interv Radiol. 2018;29:S39–40.

    Article  Google Scholar 

  82. Biederman DM, Titano JJ, Bishay VL, Durrani RJ, Dayan E, Tabori N, Patel RS, Nowakowski FS, Fischman AM, Kim E. Radiation segmentectomy versus TACE combined with microwave ablation for unresectable solitary hepatocellular carcinoma up to 3 cm: a propensity score matching study. Radiology. 2017;283:895–905.

    Article  PubMed  Google Scholar 

  83. Hatanaka T, Arai H, Kakizaki S. Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Hepatol. 2018;10:485–95.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Meek J, Fletcher S, Gauss CH, Bezold S, Borja-Cacho D, Meek M. Temporary balloon occlusion for hepatic arterial flow redistribution during Yttrium-90 radioembolization. J Vasc Interv Radiol. 2019;30:1201–6.

    Article  PubMed  Google Scholar 

  85. Bruix J, Takayama T, Mazzaferro V, et al. STORM: a phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). J Clin Oncol. 2014;32:4006.

    Article  Google Scholar 

  86. Kudo M, Ueshima K, Ikeda M, et al. Randomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial. J Clin Oncol. 2018;36:206.

    Article  Google Scholar 

  87. Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344–54.

    Article  CAS  PubMed  Google Scholar 

  88. Yu SCH, Chan SL, Lee KF, et al. Ablative chemoembolization for hepatocellular carcinoma: a prospective phase I case-control comparison with conventional chemoembolization. Radiology. 2018;287:340–8.

    Article  PubMed  Google Scholar 

Key Reading

  • Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–14.

    Article  PubMed  Google Scholar 

  • Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–80.

    Article  PubMed  Google Scholar 

  • Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind J-FH. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64:106–16.

    Article  CAS  PubMed  Google Scholar 

  • Lewandowski RJ, Gabr A, Abouchaleh N, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018;287:1050–8.

    Article  PubMed  Google Scholar 

  • Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723–50.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Early Specialization in Interventional Radiology, Department of Radiology, Medical College of Wisconsin, Froedtert Memorial Lutheran Hospital, Milwaukee, WI, USA

    Thaddeus J. Maguire

  2. Division of Hematology and Medical Oncology, Medical College of Wisconsin, Froedtert Memorial Lutheran Hospital, Milwaukee, WI, USA

    Aditya Shreenivas

  3. Department of Radiology, Division of Vascular & Interventional Radiology, Medical College of Wisconsin, Froedtert Memorial Lutheran Hospital, Milwaukee, WI, USA

    William S. Rilling

Authors
  1. Thaddeus J. Maguire
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aditya Shreenivas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William S. Rilling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thaddeus J. Maguire .

Editor information

Editors and Affiliations

  1. Professor of Radiology, Oncology & Surgery, Vascular and Interventional Radiology Johns Hopkins Hospital, Baltimore, MD, USA

    Christos Georgiades

  2. Professor of Radiology and Medicine (Oncology), Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA

    Hyun S. Kim

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Maguire, T.J., Shreenivas, A., Rilling, W.S. (2020). Hepatocellular Carcinoma: Western Experience. In: Georgiades, C., Kim, H. (eds) Image-Guided Interventions in Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-48767-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-48767-6_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-48766-9

  • Online ISBN: 978-3-030-48767-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation